glp-1 nausea legal team in kentucky Lawyer kentucky semaglutide vomiting law firm
Description
This program advances research in areas where generic product development has been limited due to scientific knowledge gaps
has dropped to 37% in 2025, down from nearly 40% in 2022, coinciding with increased GLP-1 use
The system also generated $1.5 billion in premium revenue (63% increase, reflecting the addition of approximately 160,000 MassHealth members under a new Accountable Care Organization), $2.7 billion in research and academic revenue (8% increase) and $1.7 billion in other revenue (20% increase, driven by outpatient pharmacy)
Starting in mid-2026, Medicare will begin covering these drugs for select patient groups and state Medicaid programs have the option to adopt similar coverage at these discounted rates
